Form 4: Caris Life Sciences Founder and CEO David Halbert Reports Major Share Acquisitions and Preferred Stock Conversion Post-IPO

David D. Halbert, Founder, Chairman, and CEO of Caris Life Sciences, Inc., reported substantial acquisitions of common stock and conversion of preferred shares following the company's initial public offering and a reverse stock split.

Summary

• David D. Halbert, a Director, 10% Owner, and Officer (Founder, Chairman, CEO) of Caris Life Sciences, Inc., reported changes in his beneficial ownership of the company's securities.
• On March 25, 2025, Halbert acquired 360,750 shares of Common Stock through a restricted stock unit (RSU) award, increasing his direct beneficial ownership to 2,023,250 shares.
• On June 18, 2025, an additional 413,839 shares of Common Stock were acquired via an RSU award, bringing his direct beneficial ownership to 2,437,089 shares.
• On June 20, 2025, 104,761,535 shares of Common Stock were acquired indirectly through the automatic conversion of preferred stock upon the closing of the Issuer's initial public offering.
• Following these transactions, Halbert's total indirect beneficial ownership of Common Stock stands at 121,025,002 shares.
• The reported securities reflect a one-for-four reverse stock split effective June 1, 2025.
• The preferred stock (Series A and Series B) converted into Common Stock at a ratio of 0.25 shares of Common Stock per preferred share upon the IPO closing.
• Indirect ownership is held through entities like Caris Halbert, L.P., ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd, and Caris Investment III Ltd, where Mr. Halbert exercises voting and investment power.

Sentiment

Score: 7

Explanation: The filing indicates a significant increase in common stock holdings by a key insider following an IPO and a reverse stock split, which are generally positive corporate milestones. The transactions themselves are expected and procedural.

Positives

• Significant increase in common stock holdings by a key insider (Founder, Chairman, CEO) post-IPO, indicating strong alignment with shareholder interests.
• Conversion of preferred stock into common stock simplifies the capital structure.
• The transactions are a natural consequence of the company's initial public offering, a positive milestone for the company.

Future Outlook

The transactions reflect the company's recent initial public offering (IPO) and a one-for-four reverse stock split, indicating a transition to a public company capital structure.

Management Comments

• David D. Halbert is the managing member of Caris Investment Management, LLC and the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held of record by each of the foregoing entities.
• Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Industry Context

This Form 4 filing is a standard disclosure for insider transactions following significant corporate events like an Initial Public Offering (IPO) and capital restructuring, common for companies transitioning from private to public ownership in the life sciences sector.

Comparison to Industry Standards

• As a Form 4 filing, this document primarily reports insider ownership changes and does not contain information for direct comparison to industry-specific financial or operational benchmarks.
• The reported transactions, such as RSU vesting and preferred stock conversion upon IPO, are standard mechanisms for insider equity adjustments in publicly traded companies, particularly those in the biotechnology or diagnostics space like Guardant Health (GH) or Exact Sciences (EXAS) post-IPO.

Corporate Governance

Related Party Transactions

• David D. Halbert, as Founder, Chairman, and CEO, holds indirect beneficial ownership through entities like Caris Halbert, L.P., ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd, and Caris Investment III Ltd, where he has voting and investment power. This represents a significant related-party ownership structure.

Stakeholder Impact

• Shareholders: The reverse stock split and preferred stock conversion directly impact the number and type of shares held by shareholders. The increased common stock holdings by a key insider may be viewed positively, signaling confidence.
• Employees: RSU awards are a form of employee compensation, indicating ongoing equity incentives for key personnel.

Next Steps

• Continued reporting of beneficial ownership changes by insiders as required by Section 16(a) of the Securities Exchange Act of 1934.

Key Dates

Keywords

Caris Life Sciences, CAI, Form 4, Insider Trading, Beneficial Ownership, David D. Halbert, Restricted Stock Units, RSU, Preferred Stock Conversion, IPO, Reverse Stock Split, Equity, Securities, Corporate Governance